MEITU (01357): Pixocial completes Series A equity financing.
The Meitu Company (01357) announced that all the prerequisites for the equity financing and delivery of Pixocial have been met...
"MEITU (01357) has announced that all the preconditions for the equity financing of Pixocial have been met or waived (as applicable), and the delivery to all investors will occur on December 1, 2023. After the delivery, the company will continue to hold approximately 80.62% of Pixocial's shares (based on fully diluted basis).
According to the share subscription agreement, prior to and on the delivery date, Pixocial has adopted the Pixocial Option Plan, under which approximately 7.6426 million common shares (calculated on a fully diluted and converted basis, representing approximately 6% of the issued and outstanding share capital of Pixocial) are to be reserved for issuance to several service providers.
According to the share subscription agreement, on the delivery date, and in accordance with the terms of the Pixocial Option Plan, zero-cost Pixocial options will be granted to Wu Zeyuan and Song Mingyang, enabling them to purchase approximately 1.9107 million common shares (calculated on a fully diluted and converted basis, representing approximately 1.5% of the issued and outstanding share capital of Pixocial) at an exercise price of USD 0.00001 per ordinary share."
Related Articles

Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.
Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


